Drug Profile
S-nitroso-AR545C
Latest Information Update: 29 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antiplatelets
- Mechanism of Action GPIb receptor antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 13 Jan 1999 Preclinical development for Thrombosis in Israel (Unknown route)
- 13 Jan 1999 Preclinical development for Thrombosis in USA (Unknown route)